Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly: The SENECA study

Clinica Chimica Acta

Volumn 295, Issue 1-2, 2000, Pages 1-12

  Contois, John H ^a   Wu, Alan H B ^a   Li, Zemin ^a   Feroze, Amna H ^a   Grunenberger, Fabienne ^b   Haller, Jürg ^c   Degroot, Lisette ^d   Lammi Keefe, Carol J ^e  

^a HARTFORD HOSPITAL   (United States)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d WAGENINGEN UNIVERSITY   (Netherlands)

^e UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Apolipoproteins; Cholesterol; Elderly; Europe; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; CARDIOVASCULAR RISK; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEIN(A); MALE;

EID: 0034067930     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00187-X     Document Type: Article

References (49)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc. 251:1984;351-364.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc. 251:1984;365-374.
3. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Heart Study. J Am Med Assoc. 256:1986;2835-2838.
4. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc. 256:1986;2823-2828.
5. Frick M.H., Elo E., Haapa K., et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 317:1987;1237-1245.
6. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Heart Study. J Am Med Assoc. 257:1989;2176-2180.
7. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 322:1990;1700-1707.
8. Mannien V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 85:1992;37-45.
9. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med. 62:1977;707-714.
10. Kannel W.B., Neaton J.D., Wentworth D., et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J. 112:1986;825-836.
11. Gordon D.J., Knoke J., Probstfield J.L., Superko R., Tyroler H.A. High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 74:1986;1217-1225.
12. Miller N.E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 113:1987;589-597.
13. Manninen V., Elo O., Frick H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc. 260:1988;641-651.
14. Avogaro P., Bittolo Bon G., Cazzolato G., Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis. 37:1980;69-76.
15. Sniderman A., Shapiro S., Marpole D., Skinner B., Teng B., Kwiterovich P.O. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins]. Proc Natl Acad Sci USA. 77:1980;604-608.
16. Maciejko J.J., Homes D.R., Kottke B.A., Zinsmeister A.R., Dinh D.M., Mao S.J.T. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 309:1983;385-389.
17. Durrington P.N., Hunt L., Ishola M., Kane J., Stephens W.P. Serum apolipoproteins A-I and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J. 56:1986;206-212.
18. Tasaki H., Nakashima Y., Nandate H., Yashiro A., Kawashima T., Kuroiwa A. Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am Heart J. 63:1989;1441-1445.
19. Reinhart R.A., Gani K., Arndt M.R., Broste S.K. Apolipoproteins A-I and B as predictors of angiographically defined coronary heart disease. Arch Intern Med. 150:1990;1629-1633.
20. Genest J.J., McNamara J.R., Ordovas J.M., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol. 19:1992;792-802.
21. Falco C., Estelles A., Dalmau J., Espana F., Aznar J. Influence of lipoprotein(a) levels and isoforms on fibrinolytic activity - study in families with high lipoprotein(a) levels. Thromb Haemost. 79:1998;818-823.
22. Van't Hof M.A., Hautvast J.G., Schroll M., Vlachonikolis I.G. Design, methods and participation. Eur J Clin Nutr. 45:(suppl 3):1991;5-22.
23. De Groot L.C., van Staveren W.A. Description of survey towns and populations. Euronut SENECA investigators. Eur J Clin Nutr. 45:(suppl 3):1991;23-29.
24. Kafatos A., Schlienger J.L., Deslypere J.P., Ferro-Luzzi A., Cruz J.A. Nutritional status: serum lipids. Eur J Clin Nutr. 45:(suppl 3):1991;53-61.
25. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
26. Marcovina S.M., Albers J.J., Dati F., Ledue T.B., Ritchie R.F. International Federation of Clinical Chemistry standardization project for measurements of apolipoprotein A-I and B. Clin Chem. 37:1991;1676-1682.
27. Albers J.J., Marcovina S.M., Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem. 38:1992;658-662.
28. Marcovina S.M., Albers J.J., Henderson L.O., Hannon W.H. International Federatioon of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 39:1993;773-781.
29. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W.F., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidimetric assay: results from the Framingham offspring study. Clin Chem. 42:1996;515-523.
30. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W.F., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein A-I as determined with a commercially available immunoturbidimetric assay: results from the Framingham offspring study. Clin Chem. 42:1996;507-514.
31. Bachorik P.S., Lovejoy K.L., Carroll M.D., Johnson C.L. Apolipoprotein B and A-I distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 43:1997;2364-2378.
32. Graziani M.S., Zanolla L., Righetti G., Marchetti C., Mocarelli P., Marcovina S.M. Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. Clin Chem. 44:1998;134-140.
33. Leino A., Impivaara O., Kaitsaari M., Jarvisalo J. Serum concentrations of apolipoprotein A-I, apolipoprotein B., and lipoprotein(a) in a Finnish sample. Clin Chem. 41:1995;1633-1636.
34. Jungner I., Marcovina S.M., Walldius G., Holme I., Kolar W., Steiner E. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Material. Clin Chem. 44:1998;1641-1649.
35. Baggio G., Donazzan S., Monti D., et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J. 12:1998;433-437.
36. Pepe G., Di Perna V., Resta F., et al. In search of a biological pattern for human longevity: impact of apo A-IV genetic polymorphisms on lipoproteins and the hyper-Lp(a) in centenarians. Atherosclerosis. 137:1998;407-417.
37. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J. 301:1990;1248-1251.
38. Schaefer E.J., Lamon-Fava S., Jenner J.L., et al. Lipoprotein(a) levels and risk of coronary heart disease in men. J Am Med Assoc. 271:1994;999-1003.
39. Cremer P., Nagel D., Labrot B., et al. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 24:1994;444-453.
40. Jauhianen M., Koskinen P., Enholm C., et al. Lipoprotein(a) and coronary heart disease: a nested case control study. Atherosclerosis. 89:1991;59-67.
41. Ridker P.M., Hennekens C.H., Stampfer M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Am Med Assoc. 270:1993;2195-2199.
42. Cantin B., Gagnon F., Moorjani S., et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol. 31:1998;519-525.
43. Scanu A.M., Fless G.M. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest. 85:1990;1709-1715.
44. Klezovitch O., Scanu A.M. Heterogeneity of lipoprotein(a): growing complexities. Curr Opin Lipid. 6:1995;223-228.
45. Kinlay S., Dobson A.J., Heller R.F., Dickeson J.E., Ryan S. Lipid and apolipoprotein levels in an Australian community. Med J Aust. 154:1991;170-175.
46. Zunic G., Jelic-Ivanovic Z., Spasic S., Stojiljkovic A., Majkic-Singh N. Reference values for apolipoproteins A-I and B in healthy subjects, by age. Clin Chem. 38:1992;566-569.
47. Brunner D., Slutzky G.M., Weisbort J., Schwartz S., Lingel R. Lipo- and apolipoproteins in a population survey subset in MONICA-Israel. Acta Med Scand. 728:(suppl):1988;159-164.
48. Alaupovic P., McConathy W.J., Fesmire J., Tavella M., Bard J.M. Profiles of apolipoproteins and apolipoprotein B-containing particles in dyslipoproteinemias [Review]. Clin Chem. 34:(suppl):1988;B13-27.
49. Contois JH. Lipids, apolipoproteins A-I and B, and lipoprotein(a): relationships to diet and cardiovascular disease in the elderly. The Framingham Heart Study. Dissertation, Storrs, CT: University of Connecticut, 1994.